Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis
Collectively, our findings indicate that MSCs may alleviate SSc pulmonary fibrosis by reshaping the gut microbiota, thereby offering novel scientific insights for the investigation of clinical treatment targets for SSc.
Authors
- Biao Ni (ORCID: https://orcid.org/0000-0003-1528-4707)
- Lijie Qiu
- Lina Xu
- Mingjie Gao (ORCID: https://orcid.org/0000-0003-0994-318X)
- Cuie Wei
- Bin Li (ORCID: https://orcid.org/0000-0003-2248-4002)
- Bin Liu (ORCID: https://orcid.org/0000-0003-1569-2604)
- Min Chen (ORCID: https://orcid.org/0000-0002-0676-3143)
- Shaoqiang Wang (ORCID: https://orcid.org/0000-0001-8964-474X)
- Jintao Guo
- Kang He (ORCID: https://orcid.org/0000-0002-4554-0479)
- Weice Sun
- Yufang Gong (ORCID: https://orcid.org/0000-0002-1869-1394)
- Ming Li (ORCID: https://orcid.org/0000-0002-5593-6557)
- Hongkun Fang
Institutions
- Weifang Medical University (CN)
- Weifang People's Hospital (CN)
- Weifang Chinese Medicine Hospital (CN)
Publication Details
- Journal
- Frontiers in Microbiology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fmicb.2025.1635809
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shandong Province